Special Edition: Reduction of Residual Risk in Cardiovascular Disease: Focus on Triglycerides

This special series of Diabetes Core Update is supported by an independent educational grant from Amarin Corp.

For more than 30 years, statins have been the cornerstone of lipid management to reduce the risk of cardiovascular disease (CVD) and heart-related events. These medications have been proven to effectively lower LDL cholesterol levels and CVD risk in a wide array of patient populations. But even after patients meet their LDL cholesterol goals, the risk for CVD-related events isn’t completely abolished—a significant “residual risk” remains in most populations.

In this special two-episode series made possible by an unrestricted educational grant from Amarin Corp, Diabetes Core Update will explore the concept of residual risk in CVD, while specifically discussing the role of triglycerides as a CVD risk factor and a target to reduce residual risk. In each episode, Dr. Neil Skolnik is joined by Dr. Christie Ballantyne (Professor of Medicine-Cardiology and Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine) to discuss the concept of residual risk, how to optimize cardiovascular risk reduction and when to address various factors, the role of high triglycerides in relation to other risk factors, and common clinical cases and real-world challenges to optimally reduce CVD risk in various patient populations.

Please listen to each episode by clicking on the podcast players below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Google Play, or your preferred podcast platform.